<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128296</url>
  </required_header>
  <id_info>
    <org_study_id>09-122</org_study_id>
    <secondary_id>PO1101944</secondary_id>
    <nct_id>NCT01128296</nct_id>
  </id_info>
  <brief_title>Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas</brief_title>
  <official_title>Phase I/II Study of Preoperative Gemcitabine in Combination With Oral Hydroxychloroquine (GcHc) in Subjects With High Risk Stage IIb or III Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the research study is to determine whether treating pancreatic cancer
      patients with hydroxychloroquine in combination with gemcitabine before surgery is safe. The
      secondary goal is to determine if this new treatment regimen can effectively treat pancreatic
      cancer. This study will test the safety and efficacy of this combination in two parts, or
      phases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II trial designed to assess the safety, tolerability and efficacy of
      neoadjuvant oral hydroxychloroquine (Plaquenil®) in combination with FDR gemcitabine in
      subjects with high risk IIb or III adenocarcinoma of the pancreas. Eligible subjects will be
      administered hydroxychloroquine orally once or twice daily (depending on dose) in combination
      with FDR gemcitabine (on days 1 and 15) for 31 days prior to surgical resection. Dose
      escalations of hydroxychloroquine will proceed using Storer's Up-and-Down algorithm D.
      Subjects will be monitored for side effects and tolerability of the drug. Pre- and
      post-treatment PET scans will be the primary means to assess response to therapy. Resected
      tumors will also be assessed for evidence of inhibition of autophagy as well as
      histopathologic response and margin negative resection and number of positive lymph nodes.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Experienced a Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>Number of Participants at each dose level of HCQ that experienced a Dose Limiting Toxicity (DLT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Median number of months of disease-free survival for participants receiving study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>Median number of months of overall survival for participants receiving study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS) by Response to HCQ Treatment</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Median number of months of disease-free survival in participants who did and did not experience response to HCQ treatment. Patients who had &gt;51 % increase in their LC3-II staining were classified as having a response to HCQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) by Response to HCQ Treatment</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>Median number of months of overall survival in participants who did and did not experience response to HCQ treatment. Patients who had &gt;51 % increase in their LC3-II staining were classified as having a response to HCQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 Resection Rate</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Number of participants that underwent a resection with microscopically margin-negative resection in which no gross or microscopic tumor remains in the primary tumor bed (24) / number of that completed treatment (31)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS) by CA 19-9 Response</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Median number of months of disease-free survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from &gt;0 to 225%. Per participant decreases in Ca 19-9 ranged from &gt;0 to 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) by CA 19-9 Response</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>Median number of months of overall survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or, no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from &gt;0 to 225%. Per participant decreases in Ca 19-9 ranged from &gt;0 to 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival by p53 Genetic Status</measure>
    <time_frame>Up to 35 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) by p53 Mutant Status</measure>
    <time_frame>Up to 35 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + Gemcitabine (HcGc)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine orally twice daily in combination with gemcitabine for 31 days prior to surgical resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.</description>
    <arm_group_label>Hydroxychloroquine + Gemcitabine (HcGc)</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).</description>
    <arm_group_label>Hydroxychloroquine + Gemcitabine (HcGc)</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with biopsy-proven adenocarcinoma of the pancreas

          -  staged by IIb or greater by by EUS, or tumor greater than 2.6 cm on EUS or pancreatic
             protocol helical CT scan demonstrating venous involvement

          -  Karnofsky performance status &gt;/= 70.

          -  No active second malignancy except for basal cell carcinoma of the skin

          -  Normal renal, hepatic, and hematologic function at the time of enrollment as evidenced
             by:

               -  Serum creatinine level ≤1.5 the upper limits of normal

               -  Serum total bilirubin level ≤1.5 X ULN

          -  White blood cell count &gt;/= 3.5x109/ml per ml and platelet count ≥ 100x109 per ml

          -  Age &gt;18 years.

          -  For subjects with obstructive jaundice, the biliary tract must be drained with a
             temporary plastic or a short permanent metallic biliary stent.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Subjects deemed surgically unresectable or subjects unwilling to undergo surgical
             resection.

          -  Subjects who have received chemotherapy within 12 months prior to study entry.

          -  Prior use of radiotherapy or investigational agents for pancreatic cancer.

          -  Any evidence of metastasis to distant organs (liver, lung, peritoneum).

          -  Symptomatic or endoscopic evidence of gastric outlet obstruction

          -  Concurrent malignancies with evidence of active or measurable disease except basal
             cell carcinoma of the skin

          -  Inability to adhere to study and/or follow-up procedures

          -  History of allergic reactions or hypersensitivity to the study drugs
             (hydroxychloroquine, gemcitabine).

          -  Other concurrent experimental therapy.

          -  The effects of HCQ, and gemcitabine on the developing human fetus are unknown. For
             this reason women of child-bearing potential and men must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation. All females of childbearing
             potential must have a blood test or urine study within two weeks prior to registration
             to rule out pregnancy. Should a woman become pregnant while participating in this
             study, she should inform her treating physician immediately. If a man impregnates a
             woman while participating in this study, he should inform his treating physician
             immediately as well.

          -  Because patients with immune deficiency are at increased risk of lethal infections
             when treated with bone marrow-suppressive therapy, HIV-positive patients are excluded
             from the study. For patients receiving combination anti-retroviral therapy, the
             potential impact of pharmacokinetic interactions with HCQ and gemcitabine is unknown.
             Appropriate studies may be undertaken in patients with HIV and those receiving
             combination anti-retroviral therapy in the future.

          -  Due to the risk of disease exacerbation, patients with porphyria are ineligible.

          -  Patients with psoriasis are ineligible unless the disease is well controlled and they
             are under the care of a specialist who agrees to monitor the patient for
             exacerbations.

          -  Patients requiring the use of enzyme-inducing anti-epileptic medication that includes:
             phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine are excluded.

          -  Patients with previously documented macular degeneration or diabetic retinopathy are
             excluded.

          -  Baseline EKG with QTc &gt;470 msec (including subjects on medication). Subjects with
             ventricular pacemaker for whom QT interval is not measurable will be eligible on a
             case-by-case basis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Zeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPCI/UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <results_first_submitted>August 10, 2016</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2017</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Herbert J. Zeh, III MD, FACS</investigator_full_name>
    <investigator_title>Co-Director of the UPCI GI Oncology Program, Co-Director of the UPMC Pancreatic Cancer Center</investigator_title>
  </responsible_party>
  <keyword>high risk stage IIb or III adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>35 enrolled
2 participants withdrew prior to treatment
1 participants removed from protocol after the first dose of gemcitabine due to cerebrovascular accident unrelated to study drug
1 patient removed from protocol due to allergic rash likely related to gemcitabine
31 participants remained to receive gemcitabine + HCQ treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (200 mg/Day)</title>
          <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 200 mg/day taken for 31 consecutive days until the day of surgery.</description>
        </group>
        <group group_id="P2">
          <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (400 mg/Day)</title>
          <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 400 mg/day taken for 31 consecutive days until the day of surgery.</description>
        </group>
        <group group_id="P3">
          <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (600 mg/Day)</title>
          <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 600 mg/day taken for 31 consecutive days until the day of surgery.</description>
        </group>
        <group group_id="P4">
          <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (800 mg/Day)</title>
          <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 800 mg/day taken for 31 consecutive days until the day of surgery.</description>
        </group>
        <group group_id="P5">
          <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1000 mg/Day)</title>
          <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 1000 mg/day taken for 31 consecutive days until the day of surgery.</description>
        </group>
        <group group_id="P6">
          <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1200 mg/Day)</title>
          <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 1200 mg/day taken for 31 consecutive days until the day of surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
          <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Experienced a Dose Limiting Toxicity (DLT)</title>
        <description>Number of Participants at each dose level of HCQ that experienced a Dose Limiting Toxicity (DLT).</description>
        <time_frame>Up to 31 days</time_frame>
        <population>Observed for dose-limiting toxicities or treatment delays attributed to HCQ to determine the maximum tolerated dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 200 mg/day taken for 31 consecutive days until the day of surgery.</description>
          </group>
          <group group_id="O2">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (400 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 400 mg/day taken for 31 consecutive days until the day of surgery.</description>
          </group>
          <group group_id="O3">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (600 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 600 mg/day taken for 31 consecutive days until the day of surgery.</description>
          </group>
          <group group_id="O4">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (800 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 800 mg/day taken for 31 consecutive days until the day of surgery.</description>
          </group>
          <group group_id="O5">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1000 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 1000 mg/day taken for 31 consecutive days until the day of surgery.</description>
          </group>
          <group group_id="O6">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ dose of 1200 mg/day taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Experienced a Dose Limiting Toxicity (DLT)</title>
          <description>Number of Participants at each dose level of HCQ that experienced a Dose Limiting Toxicity (DLT).</description>
          <population>Observed for dose-limiting toxicities or treatment delays attributed to HCQ to determine the maximum tolerated dose.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (DFS)</title>
        <description>Median number of months of disease-free survival for participants receiving study treatment.</description>
        <time_frame>Up to 30 months</time_frame>
        <population>Participants that completed more than 80 % of the intended dose of HCQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1200 mg/Day)</title>
            <description>Participants with pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS)</title>
          <description>Median number of months of disease-free survival for participants receiving study treatment.</description>
          <population>Participants that completed more than 80 % of the intended dose of HCQ.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.97" lower_limit="7.27" upper_limit="22.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Median number of months of overall survival for participants receiving study treatment.</description>
        <time_frame>Up to 35 months</time_frame>
        <population>Participants that completed more than 80% of the intended dose of HCQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Median number of months of overall survival for participants receiving study treatment.</description>
          <population>Participants that completed more than 80% of the intended dose of HCQ.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.83" lower_limit="11.57">Upper bound of CI not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (DFS) by Response to HCQ Treatment</title>
        <description>Median number of months of disease-free survival in participants who did and did not experience response to HCQ treatment. Patients who had &gt;51 % increase in their LC3-II staining were classified as having a response to HCQ.</description>
        <time_frame>Up to 30 months</time_frame>
        <population>Subset of participants that completed more than 80% of the intended dose of HCQ treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS) by Response to HCQ Treatment</title>
          <description>Median number of months of disease-free survival in participants who did and did not experience response to HCQ treatment. Patients who had &gt;51 % increase in their LC3-II staining were classified as having a response to HCQ.</description>
          <population>Subset of participants that completed more than 80% of the intended dose of HCQ treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response to HQC treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.03" lower_limit="6.8">Upper bound not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response to HQC treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="0.2">Upper bound not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) by Response to HCQ Treatment</title>
        <description>Median number of months of overall survival in participants who did and did not experience response to HCQ treatment. Patients who had &gt;51 % increase in their LC3-II staining were classified as having a response to HCQ.</description>
        <time_frame>Up to 35 months</time_frame>
        <population>Subset of participants that completed more than 80 % of the intended dose of HCQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) by Response to HCQ Treatment</title>
          <description>Median number of months of overall survival in participants who did and did not experience response to HCQ treatment. Patients who had &gt;51 % increase in their LC3-II staining were classified as having a response to HCQ.</description>
          <population>Subset of participants that completed more than 80 % of the intended dose of HCQ.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response to HQC treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.83" lower_limit="11.7">Upper bound of CI not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response to HQC treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.83" lower_limit="0.02">Upper bound of CI not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>R0 Resection Rate</title>
        <description>Number of participants that underwent a resection with microscopically margin-negative resection in which no gross or microscopic tumor remains in the primary tumor bed (24) / number of that completed treatment (31)</description>
        <time_frame>Up to 30 months</time_frame>
        <population>Participants that completed more than 80 % of the intended dose of HCQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>R0 Resection Rate</title>
          <description>Number of participants that underwent a resection with microscopically margin-negative resection in which no gross or microscopic tumor remains in the primary tumor bed (24) / number of that completed treatment (31)</description>
          <population>Participants that completed more than 80 % of the intended dose of HCQ.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (DFS) by CA 19-9 Response</title>
        <description>Median number of months of disease-free survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from &gt;0 to 225%. Per participant decreases in Ca 19-9 ranged from &gt;0 to 100%.</description>
        <time_frame>Up to 30 months</time_frame>
        <population>Analysis population included a total of 26 participants who received study treatment, who experienced either an increase or decrease in Ca 19-9, or no Ca 19-9 surrogate biomarker response.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS) by CA 19-9 Response</title>
          <description>Median number of months of disease-free survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from &gt;0 to 225%. Per participant decreases in Ca 19-9 ranged from &gt;0 to 100%.</description>
          <population>Analysis population included a total of 26 participants who received study treatment, who experienced either an increase or decrease in Ca 19-9, or no Ca 19-9 surrogate biomarker response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ca 19-9 Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="9.1" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Ca 19-9 Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="2.3" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) by CA 19-9 Response</title>
        <description>Median number of months of overall survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or, no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from &gt;0 to 225%. Per participant decreases in Ca 19-9 ranged from &gt;0 to 100%.</description>
        <time_frame>Up to 35 months</time_frame>
        <population>Analysis population included participants who received study treatment, who experienced either an increase or decrease in Ca 19-9, or no Ca 19-9 surrogate biomarker response</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) by CA 19-9 Response</title>
          <description>Median number of months of overall survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or, no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from &gt;0 to 225%. Per participant decreases in Ca 19-9 ranged from &gt;0 to 100%.</description>
          <population>Analysis population included participants who received study treatment, who experienced either an increase or decrease in Ca 19-9, or no Ca 19-9 surrogate biomarker response</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ca 19-9 Response (increase or decrease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" lower_limit="11.7">Upper bound of CI not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Ca 19-9 Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="5.6">Upper bound of CI not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival by p53 Genetic Status</title>
        <time_frame>Up to 35 months</time_frame>
        <population>Participants that completed more than 80 % of the intended dose of HCQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival by p53 Genetic Status</title>
          <population>Participants that completed more than 80 % of the intended dose of HCQ.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>p53 WT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="5.5">Upper bound of CI not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p53 Mutant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="6.9">Upper bound of CI not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) by p53 Mutant Status</title>
        <time_frame>Up to 35 months</time_frame>
        <population>Participants that completed more than 80 % of the intended dose of HCQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
            <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) by p53 Mutant Status</title>
          <population>Participants that completed more than 80 % of the intended dose of HCQ.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>p53 WT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="5.5">Median and Upper bound of CI not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p53 Mutant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="8.8">Upper bound of CI not reached due to too few events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day)</title>
          <description>Participants wtih pancreatic adenocarcinoma treated with two doses of fixed dose gemcitabine (1500 mg/m^2) administered (study days 3 and 17) in combination with oral HCQ (maximum dose of 1200 mg/day) taken for 31 consecutive days until the day of surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Grade 3-4 neutrophils (ANC &lt;1.0x10^9/L), Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3-4 neutrophils (ANC &lt;1.0x10^9/L), Biliary tree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, __)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, __)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/Pancreas - Other (Specify, __)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration, Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash: dermatitis associated with radiation, Chemoradiation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify, __)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Herbert Zeh, MD</name_or_title>
      <organization>UPMC CancerCenter</organization>
      <phone>412-692-2852</phone>
      <email>zehxhx@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

